HIV / AIDS

The phase IIb trial evaluated whether adding a novel regimen of monthly azithromycin to a daily dose of trimethoprim-sulfamethoxazole would decrease the rate of STI at time of delivery among pregnant women living with HIV in Cameroon.

CRISPR edit of proviral DNA tested as potential cure for HIV in first participant of phase 1/2 clinical trial.

The intervention included meeting with experts, texting services to improve and facilitate communication, and data collection and dissemination.

Yasaswi Kislovskiy, MD, MSc, specialized in reproductive infectious disease to advocate for gender equity in health care.

Among pregnant women coinfected with HIV, a higher hepatitis C viral load increased the likelihood of transmitting HCV to children.

This will include 3 trials to examine the therapy in different formulations in HIV studies.

Gender-affirming hormone therapy (GAHT) therapy consists of administration of exogenous hormones and suppression of endogenous hormone production, with the goal of obtaining characteristics more congruent with an individual’s gender identity. Here is a review of these therapies and consideration for PrEP and the risks associated with HIV in this diverse population.

There are a number of programs designed to help lower rates of infection and transmission amongst this industry's workforce in South Africa.

Investigators noted 2 distinct phases of HIV virus levels, meaning any infected cells that survive treatment can become latent, only to reignite HIV infection after antiretroviral therapy is stopped.

Texas judge Reed O’Connor ruled that requiring employers to cover the medical expense of HIV PrEP is a violation of religious freedom.

Reviewers weigh evidence for the benefit of oral PrEP protection from HIV with risk of exacerbating hepatitis B.

Taking into account the first PrEP pill was FDA approved in 2012, a clinician reflects on its significance and where the shortcomings of education and utility of it needs to be fortified.

The European Commission approved lenacapavir to treat multidrug-resistant HIV infection. The long-acting HIV treatment regimen will be marketed as Sunlenca and available in injection or tablet form.

WHO guidelines on HIV, hepatitis and STIs focus on populations with high risk of infections but low inclusion in prevention and treatment programs.

The study was longitudinal in nature, comparing at-risk people who became infected with HIV to at-risk people who did not.

Expanding Medicaid and reducing stigma can bolster equitable HIV PrEP access, Dr. Patrick Sullivan says.

After widespread implementation of HIV pre-exposure prophylaxis (PrEP) among gay and bisexual men in Australia, population-level incidence of chlamydia and gonorrhea stabilized, allaying fears that PrEP would lead to a rise in STIs, a recent study found.

At AIDS 2022, Gilead presented data suggesting Biktarvy was a safe and effective complete HIV treatment regimen, including for those coinfected with hepatitis B.

After 5 years of treatment, fostemsavir improved immunologic response and virologic outcome in patients with highly resistant HIV infection.

HIV epidemics are emerging among key populations in the Middle East and North Africa, and the region ranks lowest globally in response indicators.

An HIV-positive woman in her 60s has recovered from a simultaneous heart and kidney transplant.

Although this form of prophylaxis is highly protective, there are situations in which breakthrough infections occur.

Visceral leishmaniasis patients coinfected with HIV are vulnerable to other comorbidities including tuberculosis and cryptococcal meningitis but also to degrees of stigmatization and human rights issues.

A positive recommendation now heads to the European Commission, which can grant marketing authorization for 27 European Union member states.